Effective July 1, 2013, our new address and phone is:
23622 Calabasas Road, Suite 300,
Calabasas, CA 91302
Our products and technologies are designed to harness the power of the immune system to improve the treatment of cancer. We are developing active immunotherapies that target not only regular tumor cells, but also the cancer stem cells believed to cause cancer growth and recurrence. Our most advanced clinical programs are in glioblastoma multiforme (GBM). Our product candidates also have potential applications in other cancers with high unmet medical need.